Price
CHART BY
Frequently asked questions
What is Vita 34's market capitalization?
The market capitalization of Vita 34 is €68.33M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Vita 34?
Vita 34's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -€0.69. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Vita 34's stock?
Currently, 1 analysts cover Vita 34's stock, with a consensus target price of €6.50. Analyst ratings provide insights into the stock's expected performance.
What is Vita 34's revenue over the trailing twelve months?
Over the trailing twelve months, Vita 34 reported a revenue of €85.71M.
What is the EBITDA for Vita 34?
Vita 34's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -€2.21M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Vita 34?
Vita 34 has a free cash flow of €4.33M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Vita 34 have, and what sector and industry does it belong to?
Vita 34 employs approximately 771 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Vita 34's shares?
The free float of Vita 34 is 5.56M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- €68.33M
- EPS (TTM)
- -€0.69
- Free Float
- 5.56M
- Revenue (TTM)
- €85.71M
- EBITDA (TTM)
- -€2.21M
- Free Cashflow (TTM)
- €4.33M
Pricing
- 1D span
- €3.64€4.10
- 52W span
- €3.70€4.92
Analyst Ratings
The price target is €6.50 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. It also engages in the development of products and drugs derived from cells, tissues, and blood for medical applications. Additionally, FamiCord is active in Cell & Gene therapies and operates as a CDMO. The company was founded by Eberhard F. Lampeter on April 28, 1997 and is headquartered in Leipzig, Germany.
- Employees
- 771
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- DE000A0BL849
- Primary Ticker
- V3V
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet